Browse ANKRD17

Summary
SymbolANKRD17
Nameankyrin repeat domain 17
Aliases GTAR; KIAA0697; FLJ22206; NY-BR-16; MASK2; gene trap ankyrin repeat protein; serologically defined breast ca ......
Chromosomal Location4q21.1-q21.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Nucleus Note=Detected around the nucleolus. Localized on chromatin in a cell cycle-dependent manner.
Domain PF00023 Ankyrin repeat
PF12796 Ankyrin repeats (3 copies)
PF00013 KH domain
Function

Could play pivotal roles in cell cycle and DNA regulation (PubMed:19150984). Involved in innate immune defense against viruse by positively regulating the viral dsRNA receptors DDX58 and IFIH1 signaling pathways (PubMed:22328336). Involves in NOD2- and NOD1-mediated responses to bacteria suggesting a role in innate antibacterial immune pathways too (PubMed:23711367). Target of enterovirus 71 which is the major etiological agent of HFMD (hand, foot and mouth disease) (PubMed:17276651). Could play a central role for the formation and/or maintenance of the blood vessels of the circulation system (By similarity).

> Gene Ontology
 
Biological Process GO:0000082 G1/S transition of mitotic cell cycle
GO:0001819 positive regulation of cytokine production
GO:0001955 blood vessel maturation
GO:0002218 activation of innate immune response
GO:0002221 pattern recognition receptor signaling pathway
GO:0002697 regulation of immune effector process
GO:0002699 positive regulation of immune effector process
GO:0002753 cytoplasmic pattern recognition receptor signaling pathway
GO:0002757 immune response-activating signal transduction
GO:0002758 innate immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0002831 regulation of response to biotic stimulus
GO:0002833 positive regulation of response to biotic stimulus
GO:0006260 DNA replication
GO:0006275 regulation of DNA replication
GO:0007249 I-kappaB kinase/NF-kappaB signaling
GO:0007346 regulation of mitotic cell cycle
GO:0009615 response to virus
GO:0021700 developmental maturation
GO:0030522 intracellular receptor signaling pathway
GO:0031349 positive regulation of defense response
GO:0032103 positive regulation of response to external stimulus
GO:0039528 cytoplasmic pattern recognition receptor signaling pathway in response to virus
GO:0039529 RIG-I signaling pathway
GO:0039530 MDA-5 signaling pathway
GO:0039531 regulation of viral-induced cytoplasmic pattern recognition receptor signaling pathway
GO:0039533 regulation of MDA-5 signaling pathway
GO:0039535 regulation of RIG-I signaling pathway
GO:0042692 muscle cell differentiation
GO:0042742 defense response to bacterium
GO:0043122 regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043123 positive regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043900 regulation of multi-organism process
GO:0043902 positive regulation of multi-organism process
GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0044843 cell cycle G1/S phase transition
GO:0045088 regulation of innate immune response
GO:0045089 positive regulation of innate immune response
GO:0045787 positive regulation of cell cycle
GO:0045931 positive regulation of mitotic cell cycle
GO:0048524 positive regulation of viral process
GO:0050688 regulation of defense response to virus
GO:0050792 regulation of viral process
GO:0051052 regulation of DNA metabolic process
GO:0051145 smooth muscle cell differentiation
GO:0051147 regulation of muscle cell differentiation
GO:0051148 negative regulation of muscle cell differentiation
GO:0051150 regulation of smooth muscle cell differentiation
GO:0051151 negative regulation of smooth muscle cell differentiation
GO:0051607 defense response to virus
GO:0071695 anatomical structure maturation
GO:0090068 positive regulation of cell cycle process
GO:0098542 defense response to other organism
GO:0098586 cellular response to virus
GO:1900087 positive regulation of G1/S transition of mitotic cell cycle
GO:1900245 positive regulation of MDA-5 signaling pathway
GO:1900246 positive regulation of RIG-I signaling pathway
GO:1901987 regulation of cell cycle phase transition
GO:1901989 positive regulation of cell cycle phase transition
GO:1901990 regulation of mitotic cell cycle phase transition
GO:1901992 positive regulation of mitotic cell cycle phase transition
GO:1902806 regulation of cell cycle G1/S phase transition
GO:1902808 positive regulation of cell cycle G1/S phase transition
GO:2000045 regulation of G1/S transition of mitotic cell cycle
Molecular Function GO:0003682 chromatin binding
Cellular Component GO:0000785 chromatin
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolANKRD17
Nameankyrin repeat domain 17
Aliases GTAR; KIAA0697; FLJ22206; NY-BR-16; MASK2; gene trap ankyrin repeat protein; serologically defined breast ca ......
Chromosomal Location4q21.1-q21.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ANKRD17 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolANKRD17
Nameankyrin repeat domain 17
Aliases GTAR; KIAA0697; FLJ22206; NY-BR-16; MASK2; gene trap ankyrin repeat protein; serologically defined breast ca ......
Chromosomal Location4q21.1-q21.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ANKRD17 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 STARS Score: 4.56; FDR: 0.011 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolANKRD17
Nameankyrin repeat domain 17
Aliases GTAR; KIAA0697; FLJ22206; NY-BR-16; MASK2; gene trap ankyrin repeat protein; serologically defined breast ca ......
Chromosomal Location4q21.1-q21.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ANKRD17 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1510.542
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.210.902
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1110.928
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0740.8
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3010.914
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2140.952
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0520.9
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0110.995
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1020.962
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.9660.43
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.8480.29
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0180.708
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ANKRD17 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.14.170.339
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.15.160.373
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolANKRD17
Nameankyrin repeat domain 17
Aliases GTAR; KIAA0697; FLJ22206; NY-BR-16; MASK2; gene trap ankyrin repeat protein; serologically defined breast ca ......
Chromosomal Location4q21.1-q21.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ANKRD17. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolANKRD17
Nameankyrin repeat domain 17
Aliases GTAR; KIAA0697; FLJ22206; NY-BR-16; MASK2; gene trap ankyrin repeat protein; serologically defined breast ca ......
Chromosomal Location4q21.1-q21.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ANKRD17. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ANKRD17.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolANKRD17
Nameankyrin repeat domain 17
Aliases GTAR; KIAA0697; FLJ22206; NY-BR-16; MASK2; gene trap ankyrin repeat protein; serologically defined breast ca ......
Chromosomal Location4q21.1-q21.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ANKRD17. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolANKRD17
Nameankyrin repeat domain 17
Aliases GTAR; KIAA0697; FLJ22206; NY-BR-16; MASK2; gene trap ankyrin repeat protein; serologically defined breast ca ......
Chromosomal Location4q21.1-q21.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ANKRD17 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolANKRD17
Nameankyrin repeat domain 17
Aliases GTAR; KIAA0697; FLJ22206; NY-BR-16; MASK2; gene trap ankyrin repeat protein; serologically defined breast ca ......
Chromosomal Location4q21.1-q21.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ANKRD17 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolANKRD17
Nameankyrin repeat domain 17
Aliases GTAR; KIAA0697; FLJ22206; NY-BR-16; MASK2; gene trap ankyrin repeat protein; serologically defined breast ca ......
Chromosomal Location4q21.1-q21.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ANKRD17 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.